Syntara Limited Q4 Call: FDA gives positive feedback on amsulostat clinical pathway

Date: July 27, 2026 | Time: 9:00 PM EDT

Company Participants

• Gary Phillips – CEO, MD & Director

Conference Call Participants

• Matthew Wright

Presentation

Matthew Wright

Thank you for standing by, and welcome to the Syntara Investor Webinar and Q&A. This session follows the release of the company's Appendix 4C quarterly report for June 2026, as well as recent announcements regarding SNT-4728 and the skin scarring and myelodysplastic syndrome programs for amsulostat.

We will begin with an initial presentation of approximately 10 to 15 minutes, after which we will open the floor for questions. If you have a question you would like to submit, please type it using the Q&A function within Zoom, and we will address those at the end.

To start, I will hand over to Syntara's CEO, Gary Phillips.

Gary Phillips – CEO, MD & Director

Thanks, Matt, and thank you all for joining this morning. The usual disclaimer applies.

June Quarter Overview

It was a really good quarter. Sometimes when you are in the thick of things, it is not always easy to recognize the progress being made. However, when updating on the quarter and listing the items advanced during that period, it serves as a useful reminder of just how much actually happened.

At the beginning of the quarter, we received positive FDA feedback on the clinical development pathway for amsulostat in myelofibrosis. We presented the update and results at ASH in December last year, and this was the logical next step in presenting the full program to the FDA. We sent a full team to Washington and prepared thoroughly for the meeting. I believe we also lined up a strong set of advisors.